Thyrocare Technologies Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Thyrocare Technologies Ltd is ₹ 457 as of 30 Oct 15:30 . The P/E Ratio of Thyrocare Technologies Ltd changed from 42.2 on March 2021 to 34.2 on March 2026 . This represents a CAGR of -3.44% over 6 yearsThe P/E Ratio of Yatharth Hospital & Trauma Care Services Ltd changed from 31.3 on March 2024 to 33.9 on March 2026 . This represents a CAGR of 2.70% over 3 years The Market Cap of Thyrocare Technologies Ltd changed from ₹ 4774 crore on March 2021 to ₹ 5566 crore on March 2026 . This represents a CAGR of 2.59% over 6 yearsThe Market Cap of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 3582 crore on March 2024 to ₹ 5946 crore on March 2026 . This represents a CAGR of 18.40% over 3 years The revenue of Thyrocare Technologies Ltd for the Sep '26 is ₹ 275.24 crore as compare to the Jun '26 revenue of ₹ 244.88 crore. This represent the growth of 12.4% The revenue of Yatharth Hospital & Trauma Care Services Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 397.01 crore. This represent the decline of -100% The ebitda of Thyrocare Technologies Ltd for the Sep '26 is ₹ 48.74 crore as compare to the Jun '26 ebitda of ₹ 82.13 crore. This represent the decline of -40.66% The ebitda of Yatharth Hospital & Trauma Care Services Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 96.04 crore. This represent the decline of -100% The net profit of Thyrocare Technologies Ltd changed from ₹ 23.94 crore to ₹ 15.22 crore over 10 quarters. This represents a CAGR of -16.57% The net profit of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 30.38 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of -100.00% The Dividend Payout of Thyrocare Technologies Ltd changed from 110.36 % on March 2021 to 149.75 % on March 2026 . This represents a CAGR of 5.22% over 6 yearsThe Dividend Payout of Yatharth Hospital & Trauma Care Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Thyrocare Technologies Ltd

Thyrocare Technologies Limited was incorporated in January, 2000.
The Company operates in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. As of 31 March 2025, the Company offered more than 920 distinct tests that support early detection, preventive care and the ongoing disease monitoring.
Their 43 profiles are administered under its reputed 'Aarogyam' brand, which offers patients a suite of wellness and preventive health care tests.
The Company primarily operates its testing services through a fully automated Centralised Processing Laboratory (the CPL) and has expanded its operations to include a network of Regional Processing Laboratories (RPLs).
The company currently operates 25 RPLs, one in each of New Delhi, Coimbatore, Hyderabad, Kolkata, Bangalore, Bhopal, Mumbai Patna and Chennai, which process samples sourced from their respective regions.

About Yatharth Hospital & Trauma Care Services Ltd

Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008.
On November 3, 2021, the status converted into a Public Company and name of the Company was changed to Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC. Yatharth Hospitals and Trauma Care Services Limited is a network of super speciality hospitals across Delhi National Capital Region (NCR) and Madhya Pradesh, capitalising on the robust healthcare infrastructure in these regions to serve a wide patient base in need of tertiary care. The Company operate three super specialty hospitals in Delhi NCR, i.e., at Greater Noida, Uttar Pradesh.
The super speciality tertiary care hospital currently operates with 400 beds, including 112 critical care beds and 9 modular operation theatres, among other surgical facilities.

FAQs for the comparison of Thyrocare Technologies Ltd and Yatharth Hospital & Trauma Care Services Ltd

Which company has a larger market capitalization, Thyrocare Technologies Ltd or Yatharth Hospital & Trauma Care Services Ltd?

Market cap of Thyrocare Technologies Ltd is 7,273 Cr while Market cap of Yatharth Hospital & Trauma Care Services Ltd is 8,942 Cr

What are the key factors driving the stock performance of Thyrocare Technologies Ltd and Yatharth Hospital & Trauma Care Services Ltd?

The stock performance of Thyrocare Technologies Ltd and Yatharth Hospital & Trauma Care Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Thyrocare Technologies Ltd and Yatharth Hospital & Trauma Care Services Ltd?

As of October 31, 2026, the Thyrocare Technologies Ltd stock price is INR ₹457.0. On the other hand, Yatharth Hospital & Trauma Care Services Ltd stock price is INR ₹928.05.

How do dividend payouts of Thyrocare Technologies Ltd and Yatharth Hospital & Trauma Care Services Ltd compare?

To compare the dividend payouts of Thyrocare Technologies Ltd and Yatharth Hospital & Trauma Care Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.